Hanmi and Hanlim to win patent suit against Cipla, protecting their complexes
Hanmi Pharm and Hanlim Pharm won a patent suit against an Indian generic company, ‘Cipla.’
Conclusion of the suit has urgently attracted the industry since it was related to Hanmi Pharm and Hanmil Pharm’s self-developed allergy rhinitis complex drugs launched in 2013, ‘Motesoneplus Nasal Spray’ ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
